Meet Our Doctors

Retina Partners Midwest, P.C. physicians are dedicated to providing each patient with compassionate, state-of-the-art care in a patient-centric environment.

Dr. Raj K. Maturi, Dr. Ankur M. Shah, and Dr. Stephen J. Saxe are among our board-certified physicians. Our clinical research coordinators are friendly, knowledgeable, and certified professionals who look forward to assisting you and your family in receiving the most up-to-date treatments for retinal diseases.

Raj Maturi, M.D., F.A.S.R.S.

Raj K. Maturi, M.D., F.A.S.R.S. is a nationally recognized clinician and surgeon. He founded Retina Partners Midwest, P.C. in 1999. Dr. Maturi completed New York University School of Medicine with honors in 1993, followed by residency in ophthalmology at Baylor College of Medicine in 1997. He completed another two-year fellowship in vitreoretinal diseases and surgery at the University of Iowa in 1999, where he received the prestigious Heed Fellowship. He is one of fewer than ten surgeons worldwide who have performed suprachoroidal to subretinal delivery in the FOCUS study for macular degeneration. He has most recently been the chairman for two large international diabetic retinopathy studies. Additionally, he has been the principal investigator in over 100 research studies and has authored over 75 academic publications.

Services, Procedures, and Patient-Care Specialties

Patient Care Specialties: Comprehensive management and treatment of Diseases and Surgery of the Macula, Retina, and Vitreous, including Macular Degeneration, Diabetic Retinopathy, Retinal Vascular Occlusions and Disorders, Macular Edema (Vascular, Inflammatory, Idiopathic), Ocular Genetic Conditions, Retinal and Choroidal Dystrophies, and Disorders, Choroidal Neovascularization, Retinal Degenerative Diseases, Macular Holes, Macular Puckers, Retinal Tears and Holes, Lattice Degeneration, Retinal Detachment (All Forms), Ocular Infectious and Inflammatory Disease, Vitreous Diseases and Disorders including Vitreous Opacities and Floaters, Vitreous Hemorrhage, Posterior Vitreous Detachment, Vitreomacular Traction.

Diagnostic Services: Optical Coherence Tomography and Angiography (OCT. OCT-A), Digital Fundus Photography, Autofluorescence Photography, OPTOS Ultra-Widefield Fundus Photography and Fluorescein Angiography (UWF), Fluorescein and ICG Angiography, B-scan Ultrasonography, Multifocal Electroretinography (mfERG), Ganzfeld Electroretinography (ERG), Goldmann Visual Field (GVF), Color Vision Deficiency.

Procedures: Comprehensive Vitreous, Macular, and Retinal Surgery, including Submacular Surgery, Scleral Buckle, Retinal Laser Photocoagulation, Cryoretinopexy, Pneumatic Retinopexy, Extensive use and expertise in the use of Interventional Pharmacologic Therapies and Intravitreal Injections including Anti-Angiogenic and Anti-Inflammatory therapies, Photodynamic Therapy.

Eligible Patient Participation in Clinical Research and Clinical Trials: Extensive array of active clinical trials available to eligible patients in Macular Degeneration, Diabetic Retinopathy, and various other retinal disorders.

CURRENT POSITIONS

Vitreo-retinal diseases, surgery and Uveitis, Raj K. Maturi, MD PC, Indianapolis, 1999-present Clinical Associate Professor, Department of Ophthalmology, Indiana University School of Medicine

Chairman, Safety Committee, Aiviva Pharamceuticals, 2019 – present

Tele diagnosis consultant for Cyber-sight (ORBIS Telemedicine): Global Eye Health Consultations via the Internet 2005- present

Executive Committee Member, Diabetic Retinopathy Clinical Research Network, 2008-2011, 2013-present

Committee Member, American Academy of Ophthalmology, patient education committee, 2010-present

Editor, Retina Image Bank, 2012-present

EDUCATION

Fellow in Vitreo-retinal Diseases and Surgery, University of Iowa, Iowa City, IA 7/97 – 6/99

Resident in Ophthalmology, Baylor College of Medicine, Houston, TX 7/94 – 6/97

Intern, Transitional program, Baylor College of Medicine, Houston, TX 7/93-6/94

M.D. (with Honors), New York University School of Medicine, NY, NY June 1993

Research Scholar, National Eye Institute, NIH, Bethesda, MD 6/92 – 9/92

B.S. (Summa cum laude), Sophie Davis School of Biomedical Ed., NY, NY 1991

HONORS & AWARDS

American Society of Retina Specialists, Senior Honor Award, 2016
American Academy of Ophthalmology Achievement Award , September 2014
American Academy of Ophthalmology’s Board of Trustees & Committee of Secretaries Secretariat Award, September 2014
Lion’s Club award for work at eye hospital, Hydrabad India 2002
The Vitreous Society Annual Meeting, best video “Multifocal Electroretinography” 2001
Heed Ophthalmic Fellowship 1997
Magna Cum Laude Citation for excellence of scientific exhibit, ASNR, Seattle 1996
Successfully defended thesis in Medical and Molecular Parasitology 1993
First Place Award, Student Research Presentations 1992
Summer Research Fellowship of N.Y.U. Medical School 1991
Appalachian Fellowship 1991
Mack Lipkin Fellowship 1990-91

BOOKS and BOOK CHAPTERS

Diabetic Retinopathy for the Comprehensive Ophthalmologist, Second Edition, Unabridged, 2016 by Jonathan Walker, Robert B. Chambers Raj K. Maturi (Author)

Multifocal Electroretinography in the evaluation of macular disease, Raj K. Maturi, M.D., Yu, Minzhong, Ph.D. Editors: Ciulla, Thomas A. , Regillo, Carl D., Ocular Posterior Segment Imaging, 2003.

Non-exudative Age Related Macular Degeneration, Raj K. Maturi, M.D. R. Hampton Roy, Editor. Emedicine.com 2009

Autoimmune retinal diseases, Raj K. Maturi, M.D. and Valerie A. Purvin, M.D. R. Hampton Roy, Editor. Emedicine.com, 2009.

Stephen J. Saxe, M.D., F.A.C.S.

Stephen J. Saxe, M.D., F.A.C.S. served for twelve years as Clinical Assistant Professor of Ophthalmology at the Kellogg Eye Center, University of Michigan, training residents and fellows in all aspects of medical and surgical diseases of the retina and vitreous. Dr. Saxe completed his ophthalmology residency in 1996 at the Kresge Eye Institute, Wayne State University in Detroit, where he served as Chief Resident. This was followed by a two-year fellowship in Diseases and Surgery of the Retina at the Baylor College of Medicine and Retina Vitreous of Texas in Houston under the tutelage of world-renowned vitreoretinal surgeon Dr. H. Michael Lambert. Dr. Saxe joined Retina Partners Midwest, P.C. in 2017 and is involved in the comprehensive medical and surgical management of all vitreoretinal diseases. He has authored and contributed to a number of academic papers and actively participates in multiple ongoing clinical research studies.

Services, Procedures, and Patient-Care Specialties

Education

B.A., cum laude, Greenville College, Greenville, IL 1979-1983

M.D. Wayne State University School of Medicine, Detroit, MI 1985-1991

Honors/Awards

National Eye Institute, ARVO Travel Fellowship Award
Honors, Year III Ophthalmology Clerkship
Honors, Year III Otolaryngology Clerkship
Honors, Year IV Ophthalmology Clerkship
Honors, Year IV Ophthalmology, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
Honors, Year IV Ophthalmic Research
Honors, Consultive Cardiology Clerkship
Honors, Pediatric Ophthalmology rotation
Honors, Resident Clinic rotation
Honors, Vitreoretinal Service rotation
Honors, Veterans Administration Hospital rotation
Honors, general ophthalmology/cornea rotation
The Barsky Prize, 1st Place, best research presentation 40th Annual Kresge Eye Institute Clinical Conference
Kellogg Eye Center, Employee of the Month
2008 -2016: The Best Doctors in America (Ophthalmology)

Internship

Internship in Transitional Medicine, Wayne State University School of Medicine and the Detroit Medical Center, Detroit, MI 1992-1993.

Residency

Residency in Ophthalmology, Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine and the Detroit Medical Center, Detroit, MI 1993-1996.

Chief Resident, Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine and the Detroit Medical Center, Detroit, MI 1995-1996.

Fellowship(s)

Fellowship in Ophthalmic Pathology, Emory Eye Center, Department of Ophthalmology Emory University School of Medicine, Atlanta, GA 1991-1992.

Fellowship in Diseases and Surgery of the Retina and Vitreous, Cullen Eye Institute, Baylor College of Medicine, Houston, TX 1996-1997.

Fellowship in Diseases and Surgery of the Retina and Vitreous, Retina and Vitreous of Texas, PLLC, Houston, TX 1997-1998.

Academic Appointments

Clinical Assistant Professor of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, The University of Michigan, Ann Arbor, MI 2000-2012.

Clinical Instructor of Ophthalmology, Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, TX 1996-1997.

Board/Other Certifications

Diplomate, American Board of Ophthalmology, 1997
Diplomate, National Board of Medical Examiners, 1993
Diplomate, American Board of Ophthalmology, 2008
Fellow, American College of Surgeons, 2001
Diplomate, American Board of Ophthalmology, 2018

Memberships

American Academy of Ophthalmology, 1993-Present
American College of Surgeons, 1999-Present
American Society of Retinal Specialists, 1999-Present
New Mexico Academy of Ophthalmology, 2012-Present

Ankur M. Shah, M.D., F.A.S.R.S.

Ankur M. Shah, M.D., F.A.S.R.S. graduated with honors from Northwestern University School of Medicine in 2006. He completed his ophthalmology residency at the University of California in San Diego, serving as chief resident. He then completed a medical retina fellowship (one year) at Northwestern University Medical Center and a surgical retina fellowship at the University of Chicago (two years). Dr. Ankur Shah has been in practice over a decade. He has participated in multiple clinical research studies as a principal investigator and is welcoming our patients in Kokomo and Fort Wayne.

Services, Procedures, and Patient-Care Specialties

Education

M.D. Northwestern University, Feinberg School of Medicine, Chicago, IL-2002 – 2006

Alpha Omega Alpha (AOA) Medical Honor Society, 2006

B.S. University of Michigan, Ann Arbor, MI-1998 – 2001

Biological Anthropology with Highest Distinction

Residency

The Ophthalmology University of California – San Diego, Shiley Eye Center, San Diego, CA 2007 – 2010

The Chief Resident University of California – San Diego, Shiley Eye Center, San Diego, CA 2009 – 2010

Fellowship

Surgical Retina
University of Chicago, Chicago, IL
2014 – 2016

Medical Retina
Northwestern University, Chicago, IL
2010 – 2011

Professional Affiliations

American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Club Vit

Research

Publications

Shah AM, Grewal D. Which treatment paradigm – local or systemic therapy – best treats bilateral noninfectious uveitis?

Point/Counter: Ocular Surgery News U.S. Edition, March 10, 2020.

Gupta N, Shah AM, Jampol LM, Gill, MK. Intravitreal Bevacizumab for Choroidal Metastases Secondary to Adenocarcinoma of the Lung.

Clinical Communications – Oncology. 2015:2:2.

Shah AM, Bressler NM, Jampol LM. Does Laser Still Have a Role in the Management of Retinal Vascular and Neovascular Diseases?

American Journal of Ophthalmology 2011;152(3):332-339.

Shah AM, Oster SF, Freeman WR. Viral Retinitis After Intravitreal Triamcinolone Injection in Patients with Predisposing Medical Comorbidities.

American Journal of Ophthalmology 2010;149(3):433-440.

Abstracts and Presentations

“YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic noninfectious posterior uveitis.” Shah AM. Presented at the American Society of Retinal Specialists Annual Meeting. San Antonio, TX. October 9, 2021.

Intravitreal Bevacizumab for Choroidal Metastases Secondary to Adenocarcinoma of the Lung.” Shah AM, Gill MK, Jampol LM. Presented at the American Society of Retinal Specialists Annual Meeting. Boston, MA. August 22, 2011.

Viral Retinitis After Intravitreal Triamcinolone Injection in Patients with Predisposing Medical Comorbidities.” Shah AM, Oster SF, Freeman WR. Presented at Shiley Eye Center Alumni Research Day, La Jolla, CA. June 19, 2010.

Principal Investigator Protocols

COAST, (OPT-3002-1005) A phase III, multicenter, double-masked, randomized study to evaluate the efficacy and safety of Intravitreal OPT-302 in combination with Aflibercept, compared with Aflibercept alone, in participants with Neovascular Age-Related Macular Degeneration, 2021.

BALATON, (GR41984) A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema Secondary to Branch Retinal Vein Occlusion, 2021.

COMINO, (GR41986) A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion, 2021.

AVONELLE-X, (GR42691) A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Neovascular Age-Related Macular Degeneration, 2021.

THE NEW DAY STUDY, (01-20-005) A randomized, masked, controlled study of intravitreal Iluvien Implant as baseline therapy in patients with early Diabetic Macular Edema, 2020.

RHONE-X, (GR41987) A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macule edema, 2020.

NORSE III (ONS-5010-003) A 3-month study to assess the safety of ONS-5010 in subjects with visual impairment due to retinal disorders, 2020.

PHOTON, (VGFTe-HD-DME-1934), A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose Aflibercept in patients with Diabetic Macular Edema, 2020.

TALON, (CRTH258A2303), A 64-week, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration, 2019.

KINGFISHER, (RTH258B2305), A 12-month, 2-arm, randomized, double-masked, multicenter phase III study assessing the efficacy and safety of Brolucizumab every four weeks versus Aflibercept every four weeks in adult patients with visual impairment due to Diabetic Macular Edema, 2019.

NORSE II, (ONS-5010-002), A clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), 2019.

LUCERNE, (GR40844), A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration, 2019.

RHINE, (GR40398), A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of R06867461 (Faricimab) in patients with Diabetic Macular Edema, 2018.

Safety and Efficacy of Suprachoroidal CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion, 2018.

Sub-Investigator Protocols

LONGITUDE, (BP41783) A longitudinal, biomarker study of Anti-VEGF to explore the relationship between aqueous humor composition and multimodal retinal imaging in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, 2021.

Lpath / Pfizer Pharmaceuticals, Sub-Investigator, Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin to Treat Age-related Macular Degeneration (AMD) (Nexus), 2014-2015.

XOMA, Safety and Efficacy Study of Gevokizumab to Treat Active Noninfectious Uveitis (EYEGUARD™-A), 2014-2016.

XOMA, Sub-Investigator, Safety and Efficacy Study of Gevokizumab to Treat Noninfectious Uveitis Controlled with Systemic Treatment (EYEGUARD™-C), 2014-2016.

XOMA, Sub-Investigator, An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab to Assess Long-term Gevokizumab Safety Data (EYEGUARD™-E), 2014-2015.

Santen, Sub-Investigator, A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Noninfectious Uveitis (SAKURA), 2015-2016.

Lectures

Developments in the Management of Diabetic Retinopathy & Diabetic Macular Edema
2019 Glaucoma – Cataract Consultants, Inc. Annual Optometric CME Event

Vitreomacular Interface Disorders
2016 Prairie Eye Center Fall Optometric CME Symposium

The Evolving Role of Intravitreal Steroids in the Management of Diabetic Macular Edema
The 2016 University of Chicago Dept. of Ophthalmology and Visual Sciences Annual Research Day

Peripheral Retinal Pathology
2015 Illinois College of Optometry

Vitreoretinal Interface Disorders
2015 Glaucoma – Cataract Consultants, Inc. Annual Optometric CME Event

Peripheral Retinal Pathology
2015 Glaucoma – Cataract Consultants, Inc. Annual Optometric CME Event

Vitreoretinal Interface Disorders, 2014 University of Chicago Ophthalmology Residency Lecture Series

The Role of Vitreomacular Adhesion in Retinal Vascular and Neovascular Disease
2013 Wisconsin Academy of Ophthalmology Eye MD Symposium

Peripheral Retinal Pathology
2012 Wisconsin Optometric Association Summer Education Event

Diabetic Retinopathy
2012 Wisconsin Optometric Association Summer Education Event

Diabetic Retinopathy
2012 Aurora St. Luke’s Family Practice Residency Lecture Series

Diabetic Retinopathy
2012 Aurora St. Luke’s Endocrinology Group

Vitreoretinal Interface Disorders
2011 Northwestern University Ophthalmology Residency Lecture Series

Age-Related Macular Degeneration
2010 Northwestern University Ophthalmology Residency Lecture Series